SZSE
Every company in the roster listed on SZSE.
Every company in the roster listed on SZSE.
12 of 12 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
| 1 asset: 1 Ph 2 | MetacavirPhase 2 · Chronic Hepatitis B | None on record | — | — | — | — | |
Chengdu Kanghong Pharmaceutical002773 · SZSE | 2 assets: 2 Ph 3 | KH607Phase 3 · Major Depressive DisorderPartial signal | Dec 2027KH607 · Phase 3 | — | — | — | $56M |
China Resources Sanjiu Medical & Pharmaceutical000999 · SZSE | 2 assets: 1 Ph 3, 1 other | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 | — | $666MDec 2025 | — | $241M |
Haisco Pharmaceutical Group002653 · SZSE | 8 assets: 5 Ph 3, 1 Ph 2, 2 Ph 1 | Anrikefon (HSK21542)Phase 3 · Chronic Kidney DiseaseReliable signal | 20 Dec 2026HSK47388 · Phase 2 | — | $267MMar 2026 | — | ~$173M |
Hangzhou Zhongmei Huadong Pharmaceutical000963 · SZSE | 7 assets: 5 Ph 3, 1 Ph 2, 1 Ph 1 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | 1 Dec 2026HDM1005 · Phase 1 | — | — | — | $244M |
Huadong Medicine000963 · SZSE | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | Edaravone (TTYP01)Phase 3 · Acute Ischemic Stroke | Mar 2028Pamlectabart tismanitin · Phase 1/2 | — | — | Profitable | — |
Jiangsu Nhwa Pharmaceutical Co., Ltd.002262 · SZSE | 2 assets: 1 Ph 2, 1 Ph 1 | NH102Phase 2 · Major Depressive DisorderPartial signal | None on record | — | $207MMar 2026 | — | $92M |
Livzon Pharmaceutical Group Inc.000513 · SZSE | 1 asset: 1 Ph 3 | LecankitugPhase 3 · Psoriasis | None on record | — | — | Profitable | — |
Shenzhen Salubris Pharmaceuticals002294 · SZSE | 7 assets: 3 Ph 3, 4 Ph 2 | EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal | 12 Dec 2026SAL0137 · Phase 2 | — | $157MMar 2026 | — | $79M |
Shijiazhuang Yiling Pharmaceutical Co. Ltd002603 · SZSE | 1 asset: 1 Ph 3 | XY0206Phase 3 · Acute Myeloid Leukemia | 1 Jul 2027XY0206 · Phase 3 | — | — | — | — |
Sichuan Kelun Pharmaceutical Co., Ltd.002422 · SZSE | 1 asset: 1 Ph 1 | Brexpiprazole long-acting injection (Kelun)Phase 1 · Schizophrenia | None on record | — | — | — | — |
Zhejiang Jingxin Pharmaceutical Co., Ltd.002020 · SZSE | 2 assets: 1 Ph 2, 1 Ph 1 | JX11502MAPhase 2 · SchizophreniaPartial signal | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.